Mizuho Markets Americas LLC Acquires Shares of 126,500 Sabra Healthcare REIT, Inc. $SBRA

Mizuho Markets Americas LLC bought a new position in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) during the first quarter, Holdings Channel.com reports. The institutional investor bought 126,500 shares of the real estate investment trust’s stock, valued at approximately $2,433,000.

A number of other large investors have also made changes to their positions in SBRA. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Sabra Healthcare REIT by 6.8% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,208,600 shares of the real estate investment trust’s stock worth $61,701,000 after purchasing an additional 203,226 shares during the period. Principal Financial Group Inc. grew its position in Sabra Healthcare REIT by 21.6% in the 4th quarter. Principal Financial Group Inc. now owns 24,953,351 shares of the real estate investment trust’s stock worth $472,617,000 after purchasing an additional 4,431,897 shares in the last quarter. Legal & General Group Plc grew its position in Sabra Healthcare REIT by 16.5% during the fourth quarter. Legal & General Group Plc now owns 1,427,180 shares of the real estate investment trust’s stock valued at $27,031,000 after buying an additional 201,667 shares during the period. UBS Group AG lifted its position in shares of Sabra Healthcare REIT by 143.1% during the 4th quarter. UBS Group AG now owns 1,460,219 shares of the real estate investment trust’s stock valued at $27,657,000 after buying an additional 859,584 shares during the last quarter. Finally, Lasalle Investment Management Securities LLC purchased a new position in Sabra Healthcare REIT in the 4th quarter valued at approximately $66,938,000. 99.40% of the stock is currently owned by hedge funds and other institutional investors.

Sabra Healthcare REIT Stock Performance

NASDAQ SBRA opened at $22.03 on Friday. The business’s 50 day moving average price is $19.64 and its 200-day moving average price is $19.82. Sabra Healthcare REIT, Inc. has a fifty-two week low of $17.17 and a fifty-two week high of $22.55. The company has a market cap of $5.56 billion, a P/E ratio of 34.97, a P/E/G ratio of 1.63 and a beta of 0.65. The company has a debt-to-equity ratio of 0.96, a quick ratio of 4.72 and a current ratio of 4.72.

Sabra Healthcare REIT (NASDAQ:SBRA) last announced its earnings results on Wednesday, April 29th. The real estate investment trust reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $211.74 million for the quarter, compared to the consensus estimate of $209.20 million. Sabra Healthcare REIT had a net margin of 19.22% and a return on equity of 5.60%. The business’s revenue for the quarter was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.37 earnings per share. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. Sell-side analysts predict that Sabra Healthcare REIT, Inc. will post 1.5 earnings per share for the current year.

Sabra Healthcare REIT Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were issued a $0.30 dividend. The ex-dividend date was Friday, May 15th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 5.4%. Sabra Healthcare REIT’s dividend payout ratio (DPR) is currently 190.48%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SBRA shares. Citigroup restated a “market outperform” rating on shares of Sabra Healthcare REIT in a research report on Wednesday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sabra Healthcare REIT in a report on Wednesday. Truist Financial upped their target price on Sabra Healthcare REIT from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday. Raymond James Financial began coverage on shares of Sabra Healthcare REIT in a research note on Wednesday, June 17th. They set an “underperform” rating for the company. Finally, Citizens Jmp raised their price target on Sabra Healthcare REIT from $23.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Eight investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $22.25.

Sabra Healthcare REIT Profile

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.